The Food and Drug Administration accepted Novo Nordisk’s marketing application for an oral version of its weight-loss drug Wegovy and will decide in the fourth quarter, the Danis ...

Anthropic is preparing to carry out its first employee share buyback, valuing the firm at $61.5 billion. The initiative also ...

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.

Viking is developing what might be a game-changing medication in the segment.

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

Health Canada begins a priority review of semaglutide 2.4 mg, a weekly treatment by Novo Nordisk for MASH, a liver disease ...

More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and ...

On this week’s episode of the Readout LOUD, we review President Trump’s first 100 days, the return of biotech M&A, strong ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...